KL-140 + mFOLFOX-6

KL-140 + mFOLFOX-6 is a **combination therapy** that includes KL-140, a novel investigational drug (likely in development based on naming conventions and trial design), administered together with the standard mFOLFOX-6 chemotherapy regimen. mFOLFOX-6 is a **modified version of the FOLFOX regimen** that combines three chemotherapeutic agents: **oxaliplatin (a platinum-based DNA crosslinker), leucovorin (folinic acid) (a biomodulator potentiating 5-FU), and 5-fluorouracil (5-FU, a thymidylate synthase inhibitor, antimetabolite)**.\nThe **mechanism of action** for mFOLFOX-6 involves the inhibition of DNA synthesis and repair and disruption of pyrimidine metabolism to inhibit cancer cell proliferation. KL-140's mechanism cannot be determined from the available information, but its co-administration suggests it is intended as an adjunct in oncology, likely colorectal or gastric cancer.\nThe **primary indications** for mFOLFOX-6 are **colorectal, gastrointestinal, and small bowel cancer**, in both adjuvant and metastatic settings[2][3][5]. KL-140 is presumably under clinical development for related cancer indications.

Other names

mFOLFOX-6mFOLFOX6mFOLFOX 6